Clinical applications of transpulmonary contrast echocardiography

American Heart Journal

Volumn 137, Issue 1, 1999, Pages 144-153

  Main, Michael L ^b   Grayburn, Paul A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUNEX; BR 1; CONTRAST MEDIUM; FS 069; NC 100100; PERFLUOROPENTANE; PERFLUTREN; QW 7437; UNCLASSIFIED DRUG;

ARTICLE; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; FIBRINOLYTIC THERAPY; GENE THERAPY; HUMAN; PRIORITY JOURNAL;

EID: 0032910124     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70470-9     Document Type: Article

References (61)

1. Gramiak R, Shah PM. Echocardiography of the aortic root. Invest Radiol 1968;3:356-66.
2. De Jong N, Ten Cate FJ, Lancee CT, et al. Principles and recent developments in ultrasound contrast agents. Ultrasonics 1991; 29:324-30.
3. Meltzer RS, Tickner EG, Popp RL. Why do the lungs clear ultrasound contrast? J Ultrasound Med Biol 1980;6:263-9.
4. Geny B, Mettauer B, Muan B, et al. Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients. J Am Coll Cardiol 1993;22:1193-8.
5. Feinstein SB, Cheirif J, Ten Cate FJ, et al. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. J Am Coll Cardiol 1990;16:316-24.
6. Crouse LJ, Cherif J, Hanly DE. Opcification and border delineation improvement in patients with suboptimal border definition in routine echocardiography: results of the phase III Albunex multicenter trial. J Am Coll Cardiol 1993;22:1494-500.
7. Falcone RA, Marcovitz PA, Perez JE, et al. Intravenous Albunex during dobutamine stress echocardiography: enhanced localization of left ventricular borders. Am Heart J 1995;130:254-8.
8. Gandhok NK, Block R, Ostoic T, et al. Reduced forward output states affect the left ventricular opacification of intravenously administered Albunex. J Am Soc Echocardiogr 1997;10:25-30.
9. Shapiro JR, Reisner SA, Lichtenberg GS, et al. Intravenous contrast echocardiography with use of sonicated albumin in humans: systolic disappearance of left ventricular contrast after transpulmonary transmission. J Am Coll Cardiol 1990;16:1603-7
10. Vuille C, Nidorf M, Morissey RL, et al. Effect of static pressure on the disappearance rate of specific echocardiographic contrast agents. J Am Soc Echocardiogr 1994;7:347-54.
11. Ten Cate F, Widimsky P, Cornel JH, et al. Intracoronary Albunex: its effects on left ventricular hemodynamics, function, and coronary sinus blood flow in humans. Circulation 1993;88:2123-7
12. Keller MW, Segal SS, Kaul S, et al. The behavior of sonicated albumin microbubbles in the microcirculation: a basis for their use during myocardial contrast echocardiography. Circ Res 1989;65:458-67
13. Jayaweera AR, Edwards N, Glasheen WP, et al. In vivo myocardial kinetics of air-filled albumin microbubbles during myocardial contrast echocardiography: comparison with radiolabeled red blood cells. Circ Res 1994;74:1157-65.
14. Ismail S, Jayaweera AR, Gimple LW, et al. Relation between air-filled albumin microbubble and red cell rheology in the human myocardium: influence of echocardiographic systems and chest wall attenuation. Circulation 1996;94:445-51.
15. Meza M, Greener Y, Hunt R, et al. Myocardial contrast echocardiography: reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent. Am Heart J 1996;132:871-81.
16. Porter TR, Xie F. Visually discernible myocardial echocardiographic contrast after intravenous injection of sonicated dextrose albumin microbubbles containing high molecular weight, less soluble gas. J Am Coll Cardiol 1995;25:509-15.
17. Porter TR, Xie F, Kricsfeld A, et al. Reduction in left ventricular cavitary attenuation and improvement in posterior myocardial contrast with high molecular weight intravenous perfluorocarbon-exposed sonicated dextrose albumin microbubbles. J Am Soc Echocardiogr 1996;9:437-41.
18. Skyba DM, Camarano G, Goodman BS, et al. Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second generation echocardiographic contrast agent capable of producing myocardial opacification from a venous injection. J Am Coll Cardiol 1996;28:1292-300.
19. Porter TR, Xie F, Kilzer K. Intravenous perfluoropropane-exposed sonicated dextrose albumin produces visually evident myocardial ultrasound contrast which correlates with coronary blood flow. J Am Soc Echocardiogr 1995;8:708-10.
20. Correas JM, Quay S. EchoGen emulsion: a new ultrasound contrast agent based on phase shift colloids. Clin Radiol 1996;51:11-4.
21. Beppu S, Matsuda H, Shishido T, et al. Prolonged myocardial contrast echocardiography via peripheral venous administration of QW3600 injection (EcoGen): its efficacy and side effects. J Am Soc Echocardiogr 1997;10:11-24.
22. Grayburn PA, Erickson JM, Escobar J, et al. Peripheral intravenous myocardial contrast echocardiography using a 2% dodecafluoropentane emulsion: identification of myocardial risk area and infarct size in the canine model of ischemia. J Am Coll Cardiol 1995;26:1340-7
23. Grayburn PA. Perflenapent emulsion (EchoGen): a new long-acting phase-shift agent for contrast echocardiography. Clin Cardiol 1997;20(suppl l):1-12-8.
24. Grayburn PA, Weiss JL, Hack TC, et al. A Phase III multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (Albunex) as ultrasound contrast agents in patients with suboptimal echocardiograms. J Am Coll Cardiol. 1998;32:230-6.
25. Main ML, Escobar JF, Hall SA, et al. Safety and efficacyof QW7437, a new fluorocarbon-based echocardiographic contrast agent. J Am Soc Echocardiogr 1997;10:798-804.
26. De Jong N, Cornet R, Lancee CT. Higher harmonics of vibrating gas-filled microspheres, I: simulations. Ultrasonics 1994;32:447-53.
27. De Jong N, Cornet R, Lancee CT. Higher harmonics of vibrating gasfilled microspheres, II: measurements. Ultrasonics 1994;32:455-9.
28. Schrope BA, Newhouse VL Second harmonic ultrasonic blood perfusion measurement. Ultrasound Med Biol 1993;19:567-79.
29. Porter TR, Xie F, Shouping L, et al. Increased ultrasound contrast and decreased microbubble destruction rates with triggered ultrasound imaging. J Am Soc Echocardiogr 1996;9:599-605.
30. Porter TR, Xie F, Kricsfeld D, et al. Improved myocardial contrast with second harmonic transient response imaging in humans using intravenous perfluorocarbon-exposed sonicated dextrose albumin. J Am Coll Cardiol 1996;27:1497-501.
31. Vandenburg BF, Melton HE. Acoustic lability of albumin microspheres. J Am Soc Echocardiogr 1994;7:582-9.
32. Burns PN. Harmonic imaging with ultrasound contrast agents. Clin Radiol 1996;51(suppl 1):l-50-5.
33. Freeman AP, Giles RW, Walsh WF, et al. Regional left ventricular wall motion assessment: comparison of two-dimensional echocardiography and radionuclide angiography with contrast angiography in healed myocardial infarction. Am J Cardiol 1985;56:8-12.
34. Cohen J, Burns D, Hausner E, et al. A multicenter trial comparing FS069 and Albunex for left ventricular endocardial border delineation [abstract]. J Am Coll Cardiol 1997;29:519A.
35. Porter TR, Feng X, Kricsfeld A, et al. Improved endocardial border resolution during dobutamine stress echocardiography with intravenous sonicated dextrose albumin. J Am Coll Cardiol 1994;23:1440-3.
36. Zotz RJ, Genth S, Waaler A, et al. Left ventricular volume determination using Albunex. J Am Soc Echocardiogr 1996;9:1-8.
37. Hundley WG, Kizilbash A, Afridi I, et al. Intravenous dodecafluoropentane improves determination of left ventricular function during transthoracic echocardiography. J Am Coll Cardiol 1997;29:520A.
38. Karagounis L, Sorenson SG, Menlove RL. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol 1992;19:1-12.
39. Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;88:1361-74.
40. Armstrong WF, Mueller TM, Kinney EL, et al. Assessment of myocardial perfusion abnormalities w ith contrast-enhanced two-dimensional echocardiography. Circulation 1982;66:166.
41. Kemper AJ, O'Boyle JE, Cohen CA, et al. Hydrogen peroxide contrast echocardiography: quantification in vivo ofmyocardial risk area during coronary occlusion and of the necrotic area remaining after myocardial reperfusion. Circulation 1984;70:309-17
42. Dittrich HC, Bales GL, Kuvelas T, et al. Myocardial contrast echocardiography in experimental coronary artery occlusion with a new intravenously administered contrast agent. J Am Soc Echocardiogr 1995;8:465-74.
43. Main ML, Escobar JF, Hall SA, et al. Detection of myocardial perfusion defects in the setting of residual antegrade flow by intravenous contrast echocardiography. J Am Soc Echocardiogr. 1998;11:228-35.
44. Firschke C, Lindner JR, Wei K, et al. Myocardial perfusion imaging in the setting of coronary stenosis and acute myocardial infarction using venous injection of a second-generation echocardiographic contrast agent. Circulation 1997;96:959-67
45. Kloner RA, Ganotte CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54:1496-508.
46. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992;85:1699-705.
47. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the "no reflow" phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223-8.
48. Kaul S, Senior R, Dittrich H, et al. Detection of coronary artery disease with myocardial contrast echocardiography: comparison with 99mTc-Sestamibi single-photon emission computed tomography. Circulation 1997;96:785-92.
49. Porter TR, Li S, Kricsfeld D, et al. Detection of myocardial perfusion in multiple echocardiographic windows with one intravenous injection of microbubbles using transient response second harmonic imaging. J Am Coll Cardiol 1997;29:791-9.
50. Wei K, Jayaweera AR, Firoozan S, et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998; 97:473-83.
51. Beard JT, Byrd BF. Saline contrast enhancement of trivial Doppler tricuspid regurgitation signals for estimating pulmonary artery pressure. Am J Cardiol 1988;62:486-8.
52. Von Bibra H, Sutherland G, Becher H, et al. Clinical evaluation of left heart Doppler contrast enhancement by a saccharide-based transpulmonary contrast agent. J Am Coll Cardiol 1995;25:500-8.
53. Williams MJA, McClements BM, Picard MH. Improvement of transthoracic pulmonary venous flow Doppler signal with intravenous injection of sonicated albumin. J Am Coll Cardiol 1995;26:1741-6.
54. Izumi C, Yoshida K, Akasaka T, et al. Improved visualization of pulmonary venous flow Doppler signal by intravenous injection of sonicated albumin. Am J Cardiol 1996;78:598-600.
55. Nakatani S, Imanishi T, Terasawa A, et al. Clinical application of transpulmonary contrast-enhanced Doppler technique in the assessment of severity of aortic stenosis. J Am Coll Cardiol 1992; 20:973-8.
56. Rodrigues AG, Tardif J, Dominguez M, et al. Transthoracic echocardiographic assessment of periprosthetic mitral regurgitation using intravenous injection of sonicated albumin. Am J Cardiol 1997;79:829-34.
57. Kuecherer H, Will M, da Silva KG, et al. Contrast-enhanced Doppler ultrasound for noninvasive assessment of pulmonary artery pressure during exercise in patients with chronic congestive heart failure. Am J Cardiol 1996;78:229-32.
58. Rosenschein U, Bernstein JJ, DiSegni E, et al. Experimental ultrasonic angioplasty: disruption of atherosclerotic plaques and thrombi in vitro and arterial recanalization in vivo. J Am Coll Cardiol 1990; 15:711-7
59. Porter TR, Le Veen RF, Fox R, et al. Thrombolytic enhancement with perfluorocarbon-exposed sonicated dextrose albumin molecules. Am Heart J 1996;132:964-8.
60. Nishioka T, Luo H, Fishbein MC, et al. Dissolution of thrombotic arterial occlusion by high intensity, low frequency ultrasound and dodecafluoropentane emulsion: an in vitro and in vivo study. J Am Coll Cardiol 1997;30:561-8.
61. Porter T, Li S, Kilzer K, et al. Enhanced delivery and effectiveness of antisense oligonucleotides when bound to intravenous perfluorocarbon-filled microbubbles: effect of ultrasound and therapeutic implications [abstract]. J Am Soc Echocardiogr 1997;10:413.